I-Corps alumni company Nanopath, which spun out of Dartmouth College, recently closed a $10 million Series A funding round. The funding will support development and commercialization of their biosensing platform that transforms how women’s pelvic and gynecologic infections are diagnosed.
The round was co-led by Norwest Venture Partners and the Medtech Convergence Fund, a SV Health Investors venture fund, with participation from Gingerbread Capital and Green D Ventures.
“Nanopath’s mission is deeply rooted in improving women’s health and even more broadly, health equity for all. We envision Nanopath’s technology as the go-to platform for routine women’s health screening, allowing for clinically actionable diagnosis within a single office visit,” said Amogha Tadimety, Ph.D., co-founder and CEO of Nanopath, in a press release. “With this funding, we’re looking to build our technical team and initiate commercial and clinical partnerships to bring our technology platform to market.”